IT1250722B - ANTISENSE OLIGONUCLEOTIDES - Google Patents

ANTISENSE OLIGONUCLEOTIDES

Info

Publication number
IT1250722B
IT1250722B ITMI912117A ITMI912117A IT1250722B IT 1250722 B IT1250722 B IT 1250722B IT MI912117 A ITMI912117 A IT MI912117A IT MI912117 A ITMI912117 A IT MI912117A IT 1250722 B IT1250722 B IT 1250722B
Authority
IT
Italy
Prior art keywords
modifications
antisense oligonucleotides
concerns
antisense
ability
Prior art date
Application number
ITMI912117A
Other languages
Italian (it)
Original Assignee
Univ Degli Studi Milano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Milano filed Critical Univ Degli Studi Milano
Priority to ITMI912117A priority Critical patent/IT1250722B/en
Publication of ITMI912117A0 publication Critical patent/ITMI912117A0/en
Priority to AU23872/92A priority patent/AU2387292A/en
Priority to EP92916147A priority patent/EP0605437A1/en
Priority to PCT/EP1992/001745 priority patent/WO1993003053A1/en
Publication of ITMI912117A1 publication Critical patent/ITMI912117A1/en
Application granted granted Critical
Publication of IT1250722B publication Critical patent/IT1250722B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenzione riguarda un oligonucleotide antisenso che comprende una sequenza di nucleotidi che è caratterizzata dalla sua possibilità di ibridare in condizioni di ibridazione drastiche fino ad una parte della sequenza mRNA del recettore di progesterone umano e inoltre è caratterizzata dalla sua possibilità di bloccare la sintesi del recettore del progesterone umano, e sue modificazioni, riguarda un procedimento per la preparazione di tali oligonucleotici antisenso e di tali modificazioni riguarda composizioni farmaceutiche contenenti tali oligonucleotidi antisenso e tali modificazioni e riguarda l'uso di questi oligonucleotidi antisenso e di loro modificazioni come sostanza terapeutica.The present invention relates to an antisense oligonucleotide which comprises a sequence of nucleotides which is characterized by its ability to hybridize under drastic hybridization conditions up to a part of the mRNA sequence of the human progesterone receptor and is furthermore characterized by its ability to block the synthesis of the Human progesterone receptor, and its modifications, concerns a process for the preparation of such antisense oligonucleotics and of these modifications concerns pharmaceutical compositions containing such antisense oligonucleotides and such modifications and concerns the use of these antisense oligonucleotides and their modifications as a therapeutic substance.

ITMI912117A 1991-07-30 1991-07-30 ANTISENSE OLIGONUCLEOTIDES IT1250722B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITMI912117A IT1250722B (en) 1991-07-30 1991-07-30 ANTISENSE OLIGONUCLEOTIDES
AU23872/92A AU2387292A (en) 1991-07-30 1992-07-29 Antisense oligonucleotides
EP92916147A EP0605437A1 (en) 1991-07-30 1992-07-29 Antisense oligonucleotides
PCT/EP1992/001745 WO1993003053A1 (en) 1991-07-30 1992-07-29 Antisense oligonucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912117A IT1250722B (en) 1991-07-30 1991-07-30 ANTISENSE OLIGONUCLEOTIDES

Publications (3)

Publication Number Publication Date
ITMI912117A0 ITMI912117A0 (en) 1991-07-30
ITMI912117A1 ITMI912117A1 (en) 1993-01-31
IT1250722B true IT1250722B (en) 1995-04-21

Family

ID=11360462

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI912117A IT1250722B (en) 1991-07-30 1991-07-30 ANTISENSE OLIGONUCLEOTIDES

Country Status (4)

Country Link
EP (1) EP0605437A1 (en)
AU (1) AU2387292A (en)
IT (1) IT1250722B (en)
WO (1) WO1993003053A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1043045C (en) * 1994-04-14 1999-04-21 同济医科大学 Oligonucleotide capable of inhibiting endothelin generation
PT1982182E (en) 2006-01-19 2012-06-01 Lattec I S A novel dry stick device construction and method for determining an analyte in a sample using said dry stick device
CA2636612C (en) 2006-01-19 2013-03-26 Lattec I/S Dry stick device and method for determining an analyte in a sample

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907562A1 (en) * 1989-03-09 1990-09-13 Bayer Ag ANTISENSE OLIGONUCLEOTIDS FOR INHIBITING THE TRANSACTIVATOR TARGET SEQUENCE (TAR) AND THE SYNTHESIS OF THE TRANSACTIVATOR PROTEIN (TAT) FROM HIV-1 AND THE USE THEREOF
FR2651130B1 (en) * 1989-08-23 1991-12-13 Roussel Uclaf SEQUENCE OF ANTI-SENSE OLIGONUCLEOTIDES, ANTI-RNA MESSAGE OF TNF ALPHA, METHOD OF PREPARATION, APPLICATION AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS.

Also Published As

Publication number Publication date
AU2387292A (en) 1993-03-02
EP0605437A1 (en) 1994-07-13
WO1993003053A1 (en) 1993-02-18
ITMI912117A0 (en) 1991-07-30
ITMI912117A1 (en) 1993-01-31

Similar Documents

Publication Publication Date Title
CA2322644A1 (en) Pharmaceutical composition of topiramate
HUP0002296A2 (en) Sertraline salts and sustained-release dosage forms of sertraline
KR970706829A (en) USE OF 2'-SUBSTITUTED OLIGONUCLEOTIDES TO DOWN-REGULATING GENE EXPRESSION USING 2'-SUBSTITUTED OLIGONUCLEOTIDES FOR TREATING GENE EXPRESSION
CA2227887A1 (en) Pharmaceutical compositions of conjugated estrogens and methods for their use
BR9612291A (en) Bioadhesive solid dosage form
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
CA2023899A1 (en) Anti-sense oligonucleotide sequence, anti-rna messenger of tnf alpha, process for its preparation, use as medicament and pharmaceutical composition
EP0673252A4 (en) Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies.
FR2790757B1 (en) OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
BG104357A (en) Derivatives of cyclopentene used as motiline receptor antagonists
FR2793793B1 (en) NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
IT1250722B (en) ANTISENSE OLIGONUCLEOTIDES
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
HUP9801689A2 (en) New applications of lysozyme dimer
HUP0100044A1 (en) Modified antisense nucleotides complementary to a section of the human ha-ras gene
EP0733640A4 (en) Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
YU56702A (en) Use of fsh for treating infertility
HUP0100542A2 (en) Progestogen and antiprogestogen containing kit, process for its preparation and use of the compounds for the preparation of contraseptives
ATE384133T1 (en) RETINOLIC ACID RECEPTOR BETA-2 AND GENE THERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
KR890009919A (en) 4-heteroaryl-1,3-benzodiazepine and 2-substituted-α- (heteroaryl) benzeneethanamine, methods of preparation and use thereof as medicaments
HUP0101215A2 (en) Chrystalline form of paroxetine
DE50007708D1 (en) UNSATURATED 14.15-CYCLOPROPANO ANDROSTANES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
HUP0100634A2 (en) Pharmaceutical preparations comprising pentaerytritol tetranitrate
UA79424C2 (en) Use of fsh for treatment of infertility in women

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970730